Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.
McSweeney MD, Stewart I, Richardson Z, Kang H, Park Y, Kim C, Tiruthani K, Wolf W, Schaefer A, Kumar P, Aurora H, Hutchins J, Cho JM, Hickey AJ, Lee SY, Lai SK.
McSweeney MD, et al. Among authors: wolf w.
Bioeng Transl Med. 2022 Aug 30;8(1):e10391. doi: 10.1002/btm2.10391. Online ahead of print.
Bioeng Transl Med. 2022.
PMID: 36248234
Free PMC article.